Total Funding
34
9
Total FundingVenture - Series Unknown raised
Growth Score
-6 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
373286
c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets.
Marc Struhalla: CEO and Managing Director- Thomas Pfaadt: CFO and Managing Director
About the Company
c-LEcta operates as a biotechnology company focusing on enzyme engineering and bioprocess development for regulated markets such as food and pharmaceutical. It develops, manufactures, and commercializes application-oriented enzyme variants either as its own product or in cooperative development with industry partners.
c-LEcta offers DENARASE, a
genetically engineered endonuclease used in biotechnology for the quantitative removal of nucleic acids and viscosity reduction; and CalB Immo Plus, a hydrophobic immobilized CalB preparation. Marc Struhalla and Thomas Greiner-Stöffele founded it in 2004, with its headquarters in Leipzig in Germany.
